|Antimicrobial preparations||Antituberculosis drugs||Antifungal drugs||Antiviral preparations||Antiprotozoal drugs||Antihelmintic drugs||Other antibiotics|
Monobactams belong to a group of monocyclic β-lactams. Monobactams are obtained from the bacteria Chromobacterium violaceum. Among monobactams only aztreonam is currently used in clinical practice. It possesses a narrow spectrum of antibacterial activity and is used to treat infections caused by gram-negative aerobic flora.
Spectrum of activity
Action mechanism is associated with suppressing the formation of bacterial cell wall. Aztreonam is resistant to many β-lactamases produced by gram-negative flora. It is effective against Enterobacteriaceae and P.aeruginosa resistant to nosocomial strains resistant to cephalosporins, aminoglycosides. It does not act on acynetobacter, S.maltophilia, B.cepacia, gram-positive cocci and anaerobs.
Monobactams are indicated for the treatment of lower respiratory tract infections, intra-abdominal infections, pelvic organ infections, urogenital infections, skin and soft tissue infections, sepsis. Monobactams are actively used in combination with other preparations for the treatment of mixed infections.
Monobactams are contraindicated for patients with known reactions of hypersensitivity to monobactams or beta-lactam antibiotics. They should be used with caution in patients with liver and kidney diseases.
The most common side effects typical for monobactams include:
It is not recommended to combine the medication with carbapenems